JPS60204703A - Vibrio disease treatment agent for crustaceans - Google Patents

Abstract

PURPOSE:A vibriostatic agent that is composed of an oxytetracyclin hydrochloride, as an active ingredient, a stabilizer and a solidifier, thus being used for Crustacea such as prawns and crabs without disintegration and diffusion in sea water. CONSTITUTION:The objective vibriostatic agent for Crustacea is composed of 0.5-2pts.wt. of oxytetracyclin hydrochloride, 80-90pts.wt. of feed composed of yeast, casein or fish meal, a stabilizer such as propylene glycol, sodium ascorbinate or calcium ascorbinate and 7-15pts.wt. of a solidifier such as sodium alginate, alpha-starch or gluten.

Description

[Detailed description of the invention] The present invention relates to a therapeutic agent for Vibrio disease.

More specifically, the present invention relates to a therapeutic agent for Vibrio disease of crustaceans containing oxytetracycline hydrochloride.

It has been known to treat Vibrio disease in fish such as sea bream and yellowtail by administering a drug containing oxytetracycline hydrochloride to fish.

However, even if conventional drugs are administered as therapeutic agents for Vibrio disease in crustaceans, the drugs disintegrate and flow out into seawater, making them ineffective as therapeutic agents.

As a result of various studies to improve this drawback, we found that by solidifying a drug consisting of oxytetracycline hydrochloride, feed, a stabilizer, and a solid agent, even if the drug is administered into seawater, the drug will disintegrate and will not be absorbed into the seawater. It was found that it is useful as a therapeutic agent for Vibrio disease in crustaceans without leaking into the environment.

The present invention will be explained in detail below.

The composition of the agent for treating Vibrio disease of crustaceans of the present invention includes 0.5 to 2 parts of oxytetracytalline hydrochloride, 80 to 9 parts of feed.
0 part, 0.5 to 1.5 parts of stabilizer, and 7 to 15 parts of solid agent.

Foods include edible yeast, casein, fishmeal, etc.
Stabilizers include propylene glycol, magnesium chloride hexahydrate, sodium ascorbate, calcium ascorbate, tocopherol acetate, and the like. Solid agents include sodium alginate, α-starch, gluten, and the like.

When administering this therapeutic agent to crustaceans, it depends on the type of crustacean, but in general, a dose of 25 μ (titer) or more (as oxytetracycline hydrochloride) is given to the crustacean after sunset, depending on the type of crustacean. Administer ~60 minutes before administration for 3 to 7 consecutive days.

Crustaceans to which this therapeutic agent can be applied include prawns, crabs, and prawns.

Next, an example of manufacturing the present therapeutic agent will be shown.

Material A is a mixture of oxytetracycline hydrochloride and a stabilizer, while material B is a mixture of feed and a solid agent.

Gradually dilute and mix the A material with the B material, and finally mix the A material and B material evenly, and add 20~20~
Add 60%, knead, shape with a conventional pellet machine or similar machine, and dry to obtain a formulation. The size of the preparation should be such that the shrimp can easily handle it. For example, it is said that Vibrio disease in tiger shrimp usually occurs in amounts of 2g or more, so the size of the appropriate cylindrical solid material is 1.0 to 3 mm in diameter and 3n+m to 2Q mm in length.
degree is desirable.

Examples are shown below.

Example 1゜ Oxytetracycline hydrochloride Ig (potency), propylene glycol 0.5 g, magnesium chloride hexahydrate 0.1 g
, 0.1 g of calcium ascorbate and 0.1 g of tocopherol acetate are uniformly mixed.

On the other hand, 5 g of sodium alginate, 5 g of α-starch,
42.3 g of edible yeast, 25 g of fish meal, and 20 g of casein are mixed uniformly. Next, the two are uniformly mixed, 40 g of water is added thereto, kneaded, shaped with a pellet machine, and dried to produce a therapeutic agent for vibrio disease in prawns. The stability of this therapeutic agent, oxytetracytalin hydrochloride, is 40℃7.
The survival rate was over 90% when stored under 5% RH for 6 months (this condition is usually said to have a shelf life of 3 years).

Example 2 The nobility of the therapeutic agent obtained in Example 1 and a commercially available compound feed for shrimp (manufactured by Evian Kyowa, Kyowa Hakko Co., Ltd.) was investigated by the following method.

Sixty prawns with an average body weight of 2.2 g were used, divided into two groups of 30 each, and fed the therapeutic agent of the present invention to one group and a commercially available mixed feed to the other group for 12 days.

As a result, the amount of raw material produced in 12 days was 42.3g of the former.

The latter weighed 34.9 g. Also, the survival rate is 100% for the former.
, the latter was 93%.

This test revealed that the therapeutic agent of the present invention is produced by shrimp. In addition, we investigated the uptake of oxytecracycline hydrochloride in tiger shrimp, and analyzed the hepatopancreas and muscles over time.
The m titer showed the highest value, then gradually decreased and disappeared on the 25th day.

The latter showed a maximum titer of 6.27 ppm at 12 hours, gradually decreased thereafter, and disappeared on the 25th day. This experiment revealed that the therapeutic agent of the present invention is effective.

Example 3 12,000 prawns with mild symptoms from a group of field outbreaks of prawn vibrio disease were divided into 6 experimental tanks, each containing 2,000 prawns, and the therapeutic agent obtained in Example 1 was administered for 5 days starting from the 3rd day. . The dosage is 0.10.25.5 oxytetracycline hydrochloride per 1 kg of shrimp body weight per day.
The therapeutic agent was administered to each aquarium so that the titer was 0<100,200 mg (titer).

The number of dead prawns was checked every day for a total of 12 days, from the 2nd day before the start of administration to 5 days after the final administration. As a result, the total up to the final survey date was 94.5 in each ward in the order of the above-mentioned dosage.
%, 18.8%, 11.6%, 11.1%, ratio 3%, 7
．． The mortality rate was 8%. 10 m for 5 days after the last dose
In order of dosage areas with g (potency) or higher, 4%, 0.9%,
The mortality rate was 0.4%, 0.4%, 0.4%. Since it is said that the rate of natural death without diseases is usually less than 0.1% per day, doses of 50 mg (potency) or more are considered to be within that range. These results revealed that although 25 mg (potency) is still effective, it is desirable to administer 50 mg (potency) or more per day.

Example 4゜ww J+I W IA+m 1-Ad, J-y, i
-m I+FI MwilK*+I Mkbhhk I seriously considered it.

Symptoms were observed and bacterial tests were conducted on Kuruma shrimp (average weight 13.5 g) that were generated in the embankment ceremony (6,500 m) in the Yamaguchi area, and a treatment trial was conducted on 160,000 shrimp from a pond confirmed to have Vibrio disease. The dosage was 50+++ g (titer) of oxytetracycline hydrochloride per kg body weight per day, and the drug was administered immediately after sunset, and commercially available mixed feed was administered one hour later.

The number of days of administration was 6 days. The therapeutic agent dosage, feeding amount, days, number of dead fish, and isolation status of Vibrio bacteria in this test are shown in Table 1.

Table 1 Bacillus rioda was isolated.

*2: Since no particularly weak shrimp were observed, an attempt was made to isolate the shrimp from 9 randomly collected shrimp, but Vibrio bacteria could not be isolated.

As is clear from Table 1, the number of dead fish decreased rapidly after administration of this therapeutic agent.

Claims (2)

[Claims] (1) A therapeutic agent for Vibrio disease of crustaceans containing oxytetracycline hydrochloride (2) The therapeutic agent according to claim 1, which contains a stabilizer and a fixative and is in solid form.